SGLT-2 Inhibitor

Revision as of 09:14, 22 March 2026 by Danbot (talk | contribs) (Add See Also section)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)

Administration

  • Type: Oral Diabetes medication
  • Canagliflozin (Invokana), Dapagliflozin (Farxiga), Empagliflozin (Jardiance) are FDA approved for use in type 2 diabetes

Contraindications

  • Allergy to class/drug

Adverse Reactions

Serious

  • Euglycemic DKA[1]
  • Fournier's gangrene (rare)

Common

Mechanism of Action

  • Inhibit sodium-glucose cotransporter 2, decreasing glucose reabsorption in the proximal tubule

See Also

References

  1. ↑ FDA Drug Safety Communication: FDA warns that SGLT2 inhibitors for diabetes may result in a serious condition of too much acid in the blood
Retrieved from "https://www.wikem.org/w/index.php?title=SGLT-2_Inhibitor&oldid=389019"